SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 72 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $901,000 | +11.1% | 102,631 | -5.5% | 0.02% | +25.0% |
| Q3 2019 | $811,000 | +49.1% | 108,576 | +86.0% | 0.02% | +66.7% |
| Q2 2019 | $544,000 | -24.0% | 58,385 | -57.2% | 0.01% | -25.0% |
| Q1 2019 | $716,000 | +76.4% | 136,423 | +49.4% | 0.02% | +45.5% |
| Q4 2018 | $406,000 | +16.3% | 91,339 | +81.5% | 0.01% | +57.1% |
| Q2 2018 | $349,000 | -80.0% | 50,332 | -58.9% | 0.01% | -81.1% |
| Q1 2018 | $1,744,000 | +48.8% | 122,567 | -9.3% | 0.04% | +48.0% |
| Q4 2017 | $1,172,000 | +104.2% | 135,133 | +179.0% | 0.02% | +127.3% |
| Q3 2017 | $574,000 | +48.3% | 48,442 | +75.0% | 0.01% | +37.5% |
| Q2 2017 | $387,000 | – | 27,689 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |